Monoclonal antibodies against autoimmune RNA proteins
AssigneeThe Board of Regents for the University of Oklahoma
InventorJohn B. Harley
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies against autoimmune RNA proteins such as La/SSB, Ro/SSA, nNP, and Sm. These monoclonal antibodies which are produced by a continuous hybridoma cell line, may be used in methods for detecting the presence of selected autoimmune RNA proteins and antibodies against such proteins in biological samples, and may be incorporated into diagnostic test kits for this purpose. The monoclonal antibodies may be applied in methods for screening subjects for systemic lupus erythematosus, subacute cutaneous erythematosus, neonatal lupus, Sjogren's syndrome, complete congential heart block, and other disorders which involve the presence of antibodies against autoimmune RNA proteins.
Claims42
A continuous cell line which produces monoclonal antibodies against an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB comprising a hybridoma formed by fusing a myeloma cell with a cell capable of producing antibodies against the autoimmune RNA protein.
Hybriboma cell line Lal, ATCC No. HB 8609.
Monoclonal antibodies against an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB.
A method for detecting the presence of antibodies against an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB in a biological sample, comprising:
- contacting a composition selected from at least one of monoclonal antibodies against the selected autoimmune RNA protein and immunologically active fragments of such antibodies, in a reaction zone with a stoichiometric excess of the autoimmune RNA protein, under conditions permitting antibodyprotein binding, to produce a reactive substrate;
- removing unbound components from the reaction zone;
- contacting the biological sample with the reactive substrate in the reaction zone, under conditions permitting antibody-protein binding;
- and assaying for antibody-protein reaction occurring in the reaction zone after the sample is contacted therewith.
A method for detecting the presence of an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB in a biological sample, comprising:
- contacting a composition selected from at least one of monoclonal antibodies against the selected autoimmune RNA protein and immunologically active fragments of such antibodies, in a reaction zone with an excess of the sample, under conditions permitting antibody-protein binding;
- and
- assaying for the antibody-protein reaction occurring in the reaction zone after the sample is contacted therewith, whereby the existence of such reaction indicates the presence of an autoimmune RNA protein.
A method of screening a subject for systemic lupus erythematosus and Sjogren's syndrome, comprising:
- contacting a composition selected from at least one of monoclonal antibodies against an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB and immunologically active fragments of such antibodies, in a reaction zone with a stoichiometric excess of the autoimmune RNA protein, under conditions permitting antibody-protein binding, to produce a reactive substrate;
- removing unbound components from the reaction zone;
- contacting a serum sample from the subject with the reactive substrate, under conditions permitting antibody-protein binding;
- and
- assaying for antibody-protein reaction occurring in the reaction zone after the sample is contacted therewith, whereby the existence of such reaction indicates the presence of a symptom associated with systemic lupus erythematosus and Sjogren's syndrome.
A kit for use in assaying a biological sample for antibodies against an autoimmune RNA protein selected from the group consisting of Ro/SSA and La/SSB, comprising:
- a first medium comprising an effective amount of a composition selected from at least one of monoclonal antibodies against the selected autoimmune RNA protein and immunologically active fragments of such antibodies;
- a second medium comprising a quantity of the selected autoimmune RNA protein present in stoichiometric excess relationship to the quantity of monoclonal antibodies in the first medium;
- and
- a third medium comprising an effective amount of an enzyme-labelled immunological conjugate to the biological sample.
A continuous cell line which produces monoclonal antibodies against Ro/SSA, comprising a hybridoma formed by fusing a myeloma cell with a cell capable of producing antibodies against Ro/SSA which has been prepared by:
- immunizing an immunoresponsive animal of a first species with Ro/SSA from a second and different non-murine animal species;
- and
- recovering cells capable of producing antibodies against Ro/SSA from the immunized animal.
Dependencies are inferred from the claim text.